Systemic Lupus Erythematosus
Patients with primary antiphospholipid syndrome and systemic lupus erythematosus-associated antiphospholipid syndrome have an almost 2.5-fold risk for development of atherosclerotic plaques in carotid and femoral arteries compared with healthy control patients.
Older patients with SLE are at a low risk for the development of proteinuria.
Lupus low disease activity state has been shown to be achievable and negatively associated with early damage accrual.
Neonatal systemic lupus erythematosus syndrome develops as a result of passively acquired autoimmunity, when autoantibodies produced by the mother cross the placenta, affecting the developing fetus.
Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.
"Infodemiology" and "infoveillance" are terms used to describe an emerging approach to public health research, based on Google Trends big data monitoring and data mining.
Virginia Pascual, MD, discusses precision medicine for rheumatic diseases.
The SHARE initiative has formulated evidence-based recommendations for the diagnosis and treatment of lupus nephritis childhood-onset lupus nephritis.
Maternal systemic lupus erythematosus during pregnancy is associated with increased risk for asthma in children.
Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.
Rates of SLE mortality have declined, but remain high relative to non-SLE mortality.
Atacicept may be safe and effective for lowering disease activity and severity in patients with active systemic lupus erythematosus.
Anti-ficolin-2 autoantibodies may represent a biomarker for renal manifestations in patients with active systemic lupus erythematosus.
Low vitamin D is linked with later total organ and renal damage in patients with SLE.
EULAR and ACR jointly funded and collaborated on creating a set of criteria that can be used to more accurately identify patients with SLE for inclusion in clinical trials.
Researchers studied how BMI changes would affect disease activity in systemic lupus erythematosus
Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.
The impact of excess adiposity in SLE has not been established, despite obesity being a common comorbidity in SLE.
Little is known about differences in long-term steroid toxicity between adults with cSLE and aSLE.
The efficacy variables with the greatest effect on systemic lupus erythematous (SLE) Responder Index responder status in clinical trials include SLE Disease Activity Index improvement, concomitant medication adherence, and trial completion.
Improved survival has ushered in new challenges that inadvertently increase the risk for death in patients with SLE.
The recurrence of fetal cardiac conduction disturbances in the fetuses of women expressing anti-Ro/SSA antibodies may be influenced by the season of the year and maternal age.
Improved treatment in SLE with increased life expectancy has been accompanied by an elevated risk for developing cardiovascular diseases.
While a treat to target strategy has been proposed for managing SLE, the impact of possible disease outcomes has not been fully evaluated.
Systemic Lupus Erythematosus-Associated Cognitive Impairment May Be Identified With New Screening ToolOctober 02, 2017
The high prevalence of cognitive impairment in patients with SLE creates a need for a reliable and cost-effective screening tool.
Research revealed that hydroxychloroquine is associated with reduced LDL-C and total cholesterol levels in patients with lupus.
The diagnosis and management of shrinking lung syndrome, a rare complication of systemic lupus erythematosus, is discussed in a comprehensive review.
The risk of developing SLE in current statin users aged ≥40 years was no different than that in nonusers.
Use of the anti-apoptotic protein B-cell lymphoma 2 inhibitor venetoclax reduced total lymphocyte and disease-relevant B cells in women with SLE.
The degree of risk for cardiometabolic events and all-cause mortality appeared to increase in participants who took nonsteroidal anti-inflammatory drugs or corticosteroid drugs.
Rheumatology Advisor Articles
- Concomitant Use of Glucocorticoids and Tofacitinib in Patients With RA
- What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?
- Association Between Maternal Systemic Lupus Erythematosus and Asthma in Offspring
- Rise in Health Care Costs: Are Physician Salaries the Cause?
- Physical Activity Not Associated With Reduced Frailty Risk Among Sedentary, Older Adults
- Routine Vitamin D, Calcium Supplementation Not Associated With Fracture Reduction in Older Adults
- Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis
- Leflunomide Exposure During Pregnancy Not Associated With Increased Risk for Adverse Outcomes
- Hyaluronic Acid Injections May Delay Total Knee Replacement in Osteoarthritis
- Choosing the Right TNF Inhibitor Therapy for Rheumatoid Arthritis
- Introduction of bDMARDs Linked to Reduced Incidence Rates of Total Knee Replacement
- Disease Activity in JIA During and After Pregnancy Examined
- Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
- Reexamining the Role of Concierge Medicine in Primary Care
- Topical vs Oral NSAIDs for Rheumatoid Arthritis: Examining Cardiovascular Risks